Nuvation Bio Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 13.79 million compared to USD 20.85 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.1 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.975 USD | -0.17% |
|
-0.33% | +97.35% |
Jun. 24 | Nuvation Bio Inc.(NYSE:NUVB) added to S&P Pharmaceuticals Select Industry Index | CI |
Jun. 13 | Nuvation Bio Insider Bought Shares Worth $500,089, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.35% | 737M | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+28.55% | 31.32B | |
-8.44% | 27.4B | |
+12.18% | 26.32B | |
+41.30% | 14.07B | |
+32.46% | 12.5B | |
-6.60% | 11.23B |
- Stock Market
- Equities
- NUVB Stock
- News Nuvation Bio Inc.
- Nuvation Bio Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023